J. Kupryjanczyk et al., P53 EXPRESSION IN OVARIAN BORDERLINE TUMORS AND STAGE-I CARCINOMAS, American journal of clinical pathology, 102(5), 1994, pp. 671-676
Seventy-nine ovarian serous and mucinous borderline tumors, 36 stage I
carcinomas and 39 stage II-IV carcinomas were studied for p53 protein
accumulation with monoclonal antibody PAb1801. p53 protein was expres
sed in 14% of borderline tumors, 36% of stage I carcinomas, and 64% of
higher stage carcinomas. All immunopositive carcinomas accumulated p5
3 protein in the primary tumor, and 95% of them showed concordance in
staining among different tissue blocks. A difference in frequency of p
53 protein accumulation between stage I and higher stage serous carcin
omas was not statistically significant. p53 positivity was associated
with microinvasion, microcarcinoma and coexistent carcinoma in mucinou
s borderline tumors (P = .025). An association between p53 protein exp
ression and poor tumor differentiation in Stage I carcinomas was stati
stically significant (P = .03). p53 positivity was observed in a poorl
y differentiated endometrioid carcinoma as well as in adjacent benign
endometriotic tissue. These results suggest that p53 abnormalities may
be early events in ovarian cancer, possibly contributing to malignant
transformation of some borderline tumors, endometriosis and other car
cinoma precursors.